GlassScriptPhysician profile
Vanessa J Magee
NPI 1760807556
$8,067.73
in general payments reported to CMS, 2019-2025
29 companies · $2,138 in 2025
The $2,138 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,095 · 2022: $1,351 · 2023: $1,592 · 2024: $1,892 · 2025: $2,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,526 · Education: $95.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,526.15 |
| Education | $95.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,254.83 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,118.56 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $731.09 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $514.36 | 2021-2025 | Dupixent |
| Csl Behring | $498.10 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.87 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Optinose US, INC. | $323.29 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $284.49 | 2022-2025 | Takhzyro, Cuvitru |
| Biocryst US Sales Co., LLC | $257.19 | 2021-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $235.41 | 2025 | |
| Amgen INC. | $210.54 | 2023-2025 | Tezspire |
| Pharming Healthcare, INC. | $191.53 | 2022-2025 | Joenja, Ruconest |
| Kaleo, INC. | $179.66 | 2021-2024 | Auvi-Q |
| Lilly USA, LLC | $118.92 | 2024-2025 | Ebglyss |
| Genentech USA, INC. | $113.33 | 2023-2024 | Xolair |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $98.16 | 2021-2022 | |
| Alk-Abello, INC | $84.45 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $77.49 | 2021-2023 | |
| Covis Pharma Gmbh | $64.21 | 2021-2022 | |
| Pfizer INC. | $62.28 | 2024-2025 | |
| Octapharma USA, INC. | $58.41 | 2023-2024 | Cutaquig |
| Blueprint Medicines Corporation | $46.11 | 2024-2025 | Ayvakit |
| Novo Nordisk INC | $40.60 | 2021 | |
| Verona Pharma, INC. | $36.86 | 2025 | Ohtuvayre |
| Ars Pharmaceuticals Operations, INC. | $34.68 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $21.04 | 2025 | Ryaltris |
| Merck Sharp & Dohme LLC | $16.06 | 2023 | |
| Mylan Specialty L.P. | $15.36 | 2023 | Yupelri |
| Incyte Corporation | $14.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Magee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.